Keytruda killer Ivonescimab valued at $17B pre-approval.
Yet PD-1/VEGF bispecifics do not activate T cells or make cold tumors hot.When PD-1/VEGF hit wall, dendritic cells prime & heat the tumor activating T cells enabling bispecifics to work.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $381.6M | |||
| Open | High | Low | Value | Volume |
| 25.5¢ | 26.5¢ | 25.0¢ | $522.2K | 2.030M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 89000 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 3997 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| IMM (ASX) Chart |